Clinically relevant examples for the use of such tissue-specific promoters include for example, HLP-promoter-driven expression of human blood coagulation factor VIII in the liver for AAV5-based treatment of hemophilia A (NCT03370913) [9], or the use of the muscle-specific CK8 promoter to drive mini-dystrophin expression from AAV9 for treatment of Duchenne muscular dystrophy (NCT03368742) [10]. This evidence concerns the gene DMD and Duchenne muscular dystrophy.